Infectious Disease

St. Joseph's University Medical Center

Prader-Willi Syndrome

Syndrome

COVID-19

Remdesivir

GS-5734™

Diazoxide Choline

DCCR

Soleno Therapeutics

Gilead Sciences

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi syndrome.

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

St. Joseph's University Medical Center | Infectious Disease

Site insights

Work at this site?

Active trials

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

Trial sponsors